Trial Profile
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Jan 2024
Price :
$35
*
At a glance
- Drugs RBX 2660 (Primary)
- Indications Clostridium difficile infections
- Focus Therapeutic Use
- Acronyms PUNCH Open Label; PUNCH SOS
- Sponsors Rebiotix
- 11 Oct 2023 According to a Ferring Pharmaceuticals media release, company announced four poster presentations at Infectious Disease Week (IDWeek) 2023 for REBYOTA.
- 11 Jul 2023 According to a Ferring Pharmaceuticals media release, the integrated safety analysis of three phase 2 trials (PUNCH CD, PUNCH CD2, PUNCH Open-Label) and two phase 3(PUNCH CD3, PUNCH CD3-OLS) in Therapeutic Advances in Gastroenterology.
- 11 Jul 2023 Results presented in the Ferring Pharmaceuticals Media Release.